Drug Profile
Research programme: CNS disorder therapies - Sosei Heptares/PsychoGenics
Latest Information Update: 02 Apr 2024
Price :
$50
*
At a glance
- Originator PsychoGenics; Sosei
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders